NRx Posts $2.2M Q3 Loss as First Ketamine Launch Begins
NRXP sits 30% above its 52-week low of $1.62.
Summary
NRx reported a Q3 2026 net loss of $2.2 million, or $0.05 per share, versus $5.9 million, or $0.27 per share, a year earlier, with net patient service revenue of $1.2 million from its HOPE Therapeutics clinics. The company ended September with $19.8 million in cash and no convertible debt, following a June 2026 public offering that raised roughly $22.3 million gross. The bigger story is the commercial transition: after the October 30 FDA approval of preservative-free ketamine, a 17-person sales force is in the field, the first order is in hand, and shipments are scheduled to begin no later than January 2027. Management also disclosed a Yale collaboration supporting the Accelerated Approval pathway for NRX-100, a new subcutaneous pipeline product NRX-200, and an $11.25 million DARPA prime contract with the first two invoices approved for Q4 payment. Operating loss widened to $8.1 million from $4.0 million on launch preparation costs, so the cash balance and the pace of the ketamine rollout are the key variables. The company targets a rolling NDA submission for NRX-100 by the end of 2026.
At the time of this announcement, NRXP was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.8M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.